Tsuboi Y, Nakamura M, Maruyama M, et al. - Treatment with zonisamide for Parkinson disease (PD) resulted in improved wearing off without exacerbating dyskinesia in Japanese PD patients. In addition, dyskinesia may be improved with zonisamide 50 mg.

• Phase 2 and 3 clinical trials in Japan demonstrated zonisamide-induced improved wearing off in PD.

• In this post hoc analysis with 212 patients, data were pooled from the previous phase 2 and 3 trials to determine if zonisamide improves wearing off in PD cases without exacerbating dyskinesia.

• A significant reduction in off time and Unified Parkinson's Disease Rating Scale (UPDRS) part 4-33 score at week 12 was achieved with zonisamide 50 mg, vs placebo, without increase in UPDRS part 4-32 score.

• There was significantly higher proportion of patients taking zonisamide 50 mg who fulfilled the criterion “Off time reduced and UPDRS part 4-33 score did not increase” vs that of patients taking placebo.